ERBB3 and cancer: Restoring miR-205 levels in tamoxifen-resistant cancer cells reduced MED1 expression and enhanced tamoxifen sensitivity by disrupting MED1 expression and activation by the HER3-PI3K/Akt-MED1 axis.